Repairing cardiac tissue after myocardial infarction (MI) is one of the most challenging goals in tissue engineering. Following ischemic injury, significant matrix remodeling and the formation of avascular scar tissue significantly impairs cell engraftment and survival in the damaged myocardium. This limits the efficacy of cell replacement therapies, demanding strategies that reduce pathological scarring to create a suitable microenvironment for healthy tissue regeneration. Here, we demonstrate the successful fabrication of discrete hyaluronic acid (HA)-based microrods to provide local biochemical and biomechanical signals to reprogram cells and attenuate cardiac fibrosis. HA microrods were produced in a range of physiological stiffness and shown to degrade in the presence of hyaluronidase. Additionally, we show that fibroblasts interact with these microrods in vitro, leading to significant changes in proliferation, collagen expression and other markers of a myofibroblast phenotype. When injected into the myocardium of an adult rat MI model, HA microrods prevented left ventricular wall thinning and improved cardiac function at 6 weeks post infarct.
Introduction
Ischemic heart disease is the leading cause of death worldwide, accounting for 16% of total deaths in 2015 [1] . While advancements in preventive and acute treatment of myocardial infarctions (MI) have improved patient outcomes and reduced mortality rates, the resulting tissue damage initiates pathological repair mechanisms that culminate in the formation of non-contractile scar tissue. This progressive tissue stiffening results in additional stress on the heart and reduces cardiac output [2e4] . Currently, the lack of treatment for this maladaptive response leads to challenging chronic complications and eventual heart failure in a growing patient population.
Within the past 5 years, there have been significant efforts towards developing intramyocardial hydrogel injections for cardiac tissue repair after MI [5e9]. These hydrogels act as bulking agents to thicken and mechanically stabilize the damaged myocardium, decreasing left ventricular (LV) wall stress and limiting LV expansion. While a multitude of materials have been investigated, injectable hyaluronic acid (HA) hydrogels have gained increasing attention for cardiac tissue regeneration due to the implications of HA in wound healing [10e15] .
HA is a naturally derived polysaccharide that is produced and degraded by many cell types [16e19] . As a critical component of the ECM, HA plays roles in a range of biological processes, including angiogenesis and inflammation [17, 20, 21] . Accordingly, many HAbased scaffolds have been developed within the past decade to exploit these advantageous properties [22, 23] . While bulk HA injections have seen success in preclinical studies, there remain significant challenges that limit their clinical feasibility and efficacy.
We have previously used polymeric microrods and microfibers to act as anchors for fibroblasts to mitigate the fibrotic phenotype [24e26] . This mechanobiology approach is a promising strategy for locally reducing the formation of scar tissue without the need for soluble drugs, eliminating concerns related to systemic side effects and drug release kinetics. To date, there are no existing therapeutic strategies utilizing hyaluronic acid in a microstructure-based approach for cardiac tissue regeneration in vivo. Here, we demonstrate the development and application of injectable hyaluronic acid-based microrods for comprehensive cardiac repair after MI. These HA-based microrods are biodegradable, promote cell growth, attenuate the myofibroblast phenotype and preserve myocardial structure and function after MI.
Results

Optimization of hyaluronic acid based microrods
In order to fabricate hyaluronic acid microrods through photolithography, we adapted published protocols to functionalize HA with UV-sensitive methacrylate groups (Fig. 1A ) [27] . 1 H NMR spectroscopy confirmed the substitution of hydroxyls with methacrylate groups, showing methacrylate peaks at 5.65 ppm and 6.10 ppm (Fig. 1B) . To determine the degree of substitution, we compared the integrations of the methacrylate peaks with the acetamide peak in HA at 1.85 ppm and found that we were able to reproducibly synthesize hyaluronic acid methacrylate (HAMA) with 41 ± 3% substitution. We have previously found that microrods must have an elastic modulus of at least 20 kPa in order to significantly affect cell behavior [26] . To determine the concentration of HAMA necessary to yield microrods of desired stiffness, we measured the elastic modulus of hydrogel slabs fabricated with a range of HAMA concentrations. Atomic force microscopy measurements showed that the modulus of these hydrogels increase exponentially from 1 kPa to 160 kPa with increasing HAMA concentration (Fig. 1C) . For later studies, we used 75 mg/mL and 100 mg/mL HAMA concentrations to fabricate microrods with Young's moduli of 70 kPa and 160 kPa, respectively.
Photolithography was used to reproducibly create 15 Â 15 Â 100 mm HA microrods in a range of stiffness ( Fig. 2A) . The dimensions of the microrods were controlled by the photomask while the stiffness was controlled by total HAMA concentration in the precursor solution. Brightfield microscopy confirmed uniform fabrication of HA microrods across the wafer (Fig. 2B ). Since HA is very hygroscopic, the fabricated HA microrods exhibit moderate swelling in solution. The dimensions of fully swollen HA microrods were confirmed by labeling HA microrods with a fluorescein label and imaging with confocal microscopy (Fig. 2C ).
Degradation kinetics of hyaluronic acid microrods
We conducted degradation studies on slabs of HAMA to understand the behavior of HAMA breakdown. Slabs of HAMA at varying concentration were incubated in buffer containing 100 U/ mL, 10 U/mL and 0 U/mL of hyaluronidase. Samples were taken every two days and the degradation buffer was replenished. A carbazole-based detection assay was used to quantify the amount of HA released by degradation [28] . In samples incubated with 100 U/mL of hyaluronidase, 25 mg/mL and 50 mg/mL HAMA slabs degraded quickly and were completely disintegrated at 2 and 4 days, respectively (Fig. 3A) . As HAMA concentration increased, degradation was much slower, as seen in the 75 mg/mL and 100 mg/mL slabs, which did not completely degrade until after 3 weeks. This can be attributed to the increasing number of crosslinks that can be formed at higher HAMA concentrations, as observed with the nonlinear increases in elastic modulus with increasing HAMA. This results in a tighter mesh network in which only HAMA fragments on the surface are accessible to hyaluronidase. This is consistent with our observation that 75 mg/mL and 100 mg/mL HAMA slabs became smaller in size, but maintained their mechanical integrity (Supplemental Fig. 1A ). By contrast, 25 mg/mL and 50 mg/mL HAMA slabs became softer over a short period of time and then fully dissolved. 1 H NMR was used to quantify the modification of HA (upper panel) with methacrylate groups (red arrows). The product (lower panel) had two methacrylate peaks at 5.65 ppm and 6.10 ppm, which were compared to the acetamide peak (green arrows) at 1.85 ppm to calculate the degree of substitution. (C) A range of concentrations of HA methacrylate were used to fabricate HA hydrogels with elastic moduli between 1 kPa and 160 kPa. The data indicate the mean ± SD (n ¼ 3 per group). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
To confirm this, we compared degradation of 100 mg/mL HAMA slabs in 100 U/mL and 10 U/mL hyaluronidase. Not surprisingly, we found that slabs in 10 U/mL hyaluronidase degraded much slower than those in 100 U/mL hyaluronidase (Fig. 3B, Supplemental  Fig. 1B) . However, at two weeks, the rate of degradation for both groups became nearly identical. This suggests that there is an initial phase where there are many accessible HAMA fragments and degradation is dependent on hyaluronidase concentration; and that there is a second phase where the rate limiting factor is the number of accessible HAMA fragments on the surface of the slab. We propose that hydrolysis of the crosslinks, which occurs much slower than enzyme mediated chain scission, loosens the polymer network and is the limiting step in this phase of degradation. This suggests that geometry may be a major factor in determining degradation time, so we proceeded to repeat these studies with HA microrods.
HA microrods were made using 75 mg/mL and 100 mg/mL of HAMA and incubated in buffer containing hyaluronidase, as described above. Samples were taken every two days and measured using the carbazole assay. Interestingly, we find that there is no significant difference between the degradation of 75 mg/mL and 100 mg/mL HA microrods (Fig. 3C) . The surface area to volume ratio of HA microrods is much greater than HAMA slabs, exposing more HAMA fragments to enzyme for degradation. As a result, the degradation of the HA microrods is also much faster than the HAMA polymer slabs. The 75 mg/mL and 100 mg/mL HA microrods were 50% degraded by 1 and 2 days, respectively, compared to their HAMA slab counterparts which were 50% degraded by 3 and 6 days (Supplemental Fig. 1C ). Differential interference contrast (DIC) imaging showed that these microrods degrade by surface erosion (Fig. 3D ).
Influence of hyaluronic acid microrods on fibroblasts and myocytes in vitro
We grew fibroblasts with HA microrods to evaluate the effect of HA microrods on fibroblast behavior in vitro. Primary neonatal rat ventricular fibroblasts (NRVFs) adhered to and spread on the HA microrods, often conforming to and enveloping the entirety of the rod (Fig. 4AeB) . Paxillin staining showed that the NRVFs formed distinct focal adhesions to the edges of the microrods, potentially initiating several mechanotransduction pathways (Fig. 4C-D) . We show that fibronectin binds to the HA microrods to mediate this interaction in fibroblast/myocyte co-culture (Supplemental Fig. 2) . While a key binding partner to HA, CD44 was not found to be localized to the HA microrod and was instead present over the entire fibroblast membrane (Supplemental Fig. 3 ), suggesting that CD44 is not mediating these physical interactions.
Interestingly, interaction with HA microrods increased fibroblast proliferation when cultured over three days (Fig. 4E) . NIH-3T3 fibroblasts grown with HA microrods in a 1:5 ratio of microrods:cells had increased proliferation rates compared to control cells grown on tissue culture plastic (p < 0.01). This contrasts with previous studies using polyethylene glycol (PEG)-based microrods, which reduced fibroblast proliferation [26] . This can be attributed to HA having additional cell growth properties compared to PEG, which is considered relatively bioinert. Despite the increased proliferation of fibroblasts, gene expression studies showed a decrease in key fibrosis markers. In cells grown with HA microrods, there was a dose-dependent decrease in expression of collagen I (Col1A2) and alpha smooth muscle actin (aSMA), markers of a myofibroblast phenotype (Fig. 4F) . In cells cultured in a 1:20 ratio of microrods:cells, Col1A2 expression was reduced to 0.31 ± 0.04 fold expression relative to cells grown without microrods (p < 0.001) while aSMA was reduced to 0.09 ± 0.02 fold expression (p < 0.001).
This effect was more profound when the number ofmicrorods was increased to 1 per 5 cells. Additionally, HA microrods significantly reduced TGFb1 expression and Smad3 expression (Fig. 4G , p < 0.05). These data suggest that the HA microrods act on the TGFb-signaling pathway to reduce the myofibroblast phenotype. We further examined the effect of HA microrods on the expression of matrix metalloproteinases (MMPs), specifically MMP2 and MMP9. These MMPs are upregulated following myocardial infarction to facilitate the initial breakdown and remodeling of the ECM. We found that MMP2 was significantly reduced in fibroblasts cultured with HA microrods compared to control cells (Fig. 4H , p < 0.05), suggesting that HA microrods may attenuate aberrant ECM breakdown during the initial days after MI.
Neonatal rat ventricular myocytes (NRVMs) were grown with HA in solution or HA microrods for 48 h to elucidate their effects on cardiomyocytes. Kymographs were derived from line scans under DIC illumination to determine the beats per minute and time to peak tension (Supplemental Fig. 4 ) [29] . No significance was found between groups, suggesting that neither HA microrods nor free HA interfere with the contractile properties of the NRVMs.
Taken together, these results suggest that HA microrods show promise as a therapeutic strategy to promote regenerative processes in the infarcted myocardium while mitigating pathological scarring.
Influence of hyaluronic acid microrods in vivo
An infarct was induced in rats by ischemia-reperfusion to generate a cardiac fibrosis model. After 48 h, HA microrods, soluble HA or saline were delivered into the infarct zone by ultrasoundguided, transthoracic injection. Total HA mass was kept equal for soluble HA and HA microrod injections to account for the material effect of HA. After 6 weeks, the rats were sacrificed and hearts were harvested and fresh frozen for histological analyses. Cryosections of heart tissue were stained with hematoxylin and eosin (H&E), Masson's trichrome and Picrosirius red to evaluate the effect of microrod injection on the progression of cardiac fibrosis, as compared to injections of soluble HA or saline (Fig. 5A) .
Wall thickness measurements were performed on sections throughout the heart where the left ventricle cavity was visible. The left ventricular wall of hearts treated with HA microrods had greater minimum wall thickness (1.22 ± 0.38 mm) compared to saline treated hearts (0.70 ± 0.24 mm), which exhibited significant Fig. 3 . Surface area and crosslinking density affect enzyme mediated degradation of crosslinked HA. (A) HA hydrogels made from higher HAMA concentration have reduced rates of hyaluronidase-mediated degradation due to increased crosslinking density (n ¼ 3 per group). (B) 100 mg/mL HA hydrogels degraded in a range of hyaluronidase concentration suggest biphasic degradation patterns consisting of enzymatic degradation of accessible fragments on the surface. Hydrolysis creates new accessible fragments which are degraded by enzyme in the second, slower phase of degradation (100 U/mL: n ¼ 3, 10 U/mL: n ¼ 2, PBS: n ¼ 3) (C) Crosslinking density has limited effect on HA microrod degradation due to high surface area to volume ratio (n ¼ 3 per group). (D) Differential interference contrast (DIC) images of 100 mg/mL HA microrods incubated in 100 U/mL hyaluronidase for 10 days (right) demonstrates surface erosion of microrods. The data are presented as the mean ± SD. Scale bars ¼ 100 mm.
wall thinning (Fig. 5B , p < 0.05). Animals treated with HA solution had moderate wall thinning compared to saline treated and HA microrod treated hearts (1.03 ± 0.21 mm). Heart sections were then stained with Masson's trichrome and Picrosirius red to quantify the size and collagen content of the infarcts. A comparison of rats treated with HA microrods or soluble HA to those treated with saline showed moderate, although not significant, reduction in collagen deposition in the free wall of the left ventricle (Supplemental Fig. 5 , p ¼ 0.1).
These morphological improvements also translated to improved functional outputs. At 6 weeks, stroke volume was significantly greater in animals treated with HA microrods compared to animals treated with saline (Supplemental Fig. 6C , p < 0.01). Change in ejection fraction (EF) was determined by taking the difference in ejection fraction measured at 2 days (before injection) and 6 weeks. Rats treated with HA microrods have a positive improvement in ejection fraction (5.91% ± 3.67%) compared to HA solution controls (À0.36% ± 4.20%, p < 0.05) and saline controls (À8.22% ± 7.28%, p < 0.001). Animals treated with soluble HA also exhibited significant improvements in ejection fraction compared to saline (p < 0.01), suggesting beneficial effects from the material alone. There was no significant difference in left ventricular end diastolic volume (LSEDV) and left ventricular end systolic volume (LVESV) (Supplemental Fig. 6AeB ).
Examining the HA microrod injection area, we noted that the collagen deposited around the microrods was much less dense and not visible under polarized light, suggesting a local decrease in collagen deposition and maturation (Fig.  6AeE) . Immunofluorescence staining with markers of vimentin for fibroblasts and CD68 for macrophages indicated that both CD68-positive macrophages and vimentin-positive, CD68-negative fibroblasts were present at the injection site (Supplemental Fig. 7A ). Additionally, we found that fibroblasts surrounding the HA microrods had more rounded nuclei compared to those found away from the injection site, which were spindle shaped and characteristic of activated myofibroblasts (Supplemental Fig. 7B ). Immunofluorescent staining of actin and paxillin also showed that cells within the injection site interacted with the HA microrods and formed focal adhesions along the edges of the rods (Fig. 6FeI) . It is likely that this interaction locally reduces fibroblast activation in vivo as was seen in vitro.
Discussion
In this work, we developed a novel materials-based strategy that combines the wound healing properties of hyaluronic acid with microtopographical cues to attenuate the fibrotic phenotype and encourage the repair of damaged cardiac tissue after MI. We fabricated discrete microrods using a photocrosslinkable derivative of HA, characterized their enzyme-mediated degradation, and demonstrated localized anti-fibrotic effects using in vitro and in vivo models.
Previous studies have utilized bulk HA injections to mechanically support the damaged myocardium and preserve cardiac function after MI [10e15]. These strategies typically use biocompatible crosslinking chemistries to form the HA hydrogel in situ. While this allows for noninvasive catheter-based delivery, the gelation kinetics of HA in these cases can present significant challenges. Rapid gelation can lead to clogging of the catheter during the multiple injections required for treatment, while slow gelation results in diffusion of the hydrogel material into the tissue, leading to compromised hydrogel structure and mechanical properties [30e32]. Utilizing a rigorous interdisciplinary approach, we developed HA microrods to overcome these limitations. These discrete microstructures were fully crosslinked and characterized before injection and can be delivered to the myocardial wall by catheter injection without risk of clogging. Additionally, the ability to crosslink prior to injection gives tighter control over cell shaped morphology and hydrogel stiffness in the physiologic range, which are both crucial properties for mechanotransduction [33e35] .
Within the past several decades, mechanical signaling has gained appreciation as a powerful mechanism for controlling cell behavior [33e41]. This includes mechanical stiffness, shear forces and topography. In contrast to bulk polymer injections that reduce wall stress by providing mechanical support and preventing LV dilation, discrete HA microrods provide local micromechanical and biochemical signals to reprogram the cells of the myocardium. We have used both polypropylene microfibers and PEG microstructures to supply external mechanical cues and reduce myofibroblast differentiation [24e26]. HA microrods were shown to attenuate the fibrotic response to a greater degree than previously developed materials, likely due to the added biochemical effects of HA ( Fig. 4E  and F) . Chopra et al. reported the role of HA in enhancing integrin mediated mechanotransduction [42] . Mesenchymal stem cells and fibroblasts were able to anchor to soft HA hydrogels containing fibronectin and observed increased rates of proliferation compared to soft polyacrylamide gels with fibronectin. Our cell proliferation data are consistent with these results, suggesting that the proproliferative effects of HA are preserved. Additionally, expression of key myofibroblast markers, aSMA and collagen 1, were reduced in NIH-3T3 fibroblasts to a greater extent compared to our studies with PEG microrods, an inert microtopographic cue [26] .
The results of our in vivo experiments support these observations as well. The introduction of HA microrods 2 days after the initial infarct provides anchors for fibroblasts, macrophages and other cell types. Cells found at the injection site interacted with the microrods through focal adhesions, likely due to the increased stiffness relative to surrounding tissue (Fig. 6FeI) . We propose that this stiffness differential leads to attenuation of the myofibroblast phenotype, manifesting in decreased deposition of collagen, reduced wall thinning and improved cardiac output. Similar to our in vitro results, HA microrods improved LV ejection fraction (5.91% ± 3.67%) to a greater degree as compared to previous studies using PEG microrods (À2.59% ± 8.11%) [24] . At 6 weeks, cardiac function of HA microrod treated hearts surpassed baseline, postinfarct function, highlighting the potential of this technology to promote endogenous repair mechanisms not previously seen in materials-based approaches. We investigated whether this was due solely to the biological effect of HA by injecting a solution of HA into the heart wall after MI. The concentrations used were not high enough to generate a stiff gel, yet there were also improvements on cardiac function (Fig. 5C ). This is likely due to the wound healing properties of HA, which may contribute to the results seen in studies involving bulk HA injections [20e22,43] . We originally hypothesized that fibroblasts bind to HA microrods via CD44 receptors on the cell surface, activating a sequence of signaling cascades that induce phenotypic changes. Fibroblasts display a high content of CD44 receptor and conform well to the microrod topography, suggesting that fibroblasts are responsive to HA microrods in the local environment (Supplemental Fig. 3 ). However, both myocytes and fibroblasts exhibit focal adhesions to the HA microrod contour (Fig. 4AeD, Supplemental Fig. 3 ). The deposition of fibronectin to HA explains how cells are able to attach to HA, a material that is traditionally believed to be nonadhesive (Supplemental Fig. 2 ). This is consistent with previous reports that HA is nonadherent during the first few hours of culture, but becomes adherent and amenable to cell attachment after several hours have passed [44] . One possibility is that CD44 facilitates fibroblast association with the HA microrods, promoting altered gene expression levels (Fig. 4F) while fibronectin supports continuous attachment [45] . Additionally, it has been shown that modification of the HA backbone can reduce its affinity for CD44 [46] . It is possible that our~41% modification of the 6C-OH is sufficiently high that it impairs the affinity of CD44 on the cell surface to the HA microrods. We therefore hypothesize that integrin binding is a key mechanism of interaction between fibroblasts and HA microrods, which may be amplified by other pathways involving HA and resulting in greater attenuation of the fibrotic phenotype. Additional investigation is necessary to elucidate the precise interactions and mechanisms for these phenotypic changes.
A significant advantage of HA microrods is that they are degradable by native physiological processes [17, 19, 21, 22, 43, 47, 48] . After attenuating the fibrotic response in the first few days after injection, these microrods degrade after several months to accommodate new tissue growth. While several studies have investigated the degradation behavior of covalently crosslinked HA hydrogels, it is necessary to characterize each new formulation since molecular weight, degree of methacrylation and weight percent can drastically affect degradation. In our study, we use lower molecular weight HA in our synthesis to achieve high degrees of methacrylation (Fig. 1B) . Additionally, we can get higher concentrations of low molecular weight HA (LMWHA) compared to high molecular weight HA (HMWHA), allowing for fabrication of hydrogels in a greater range of stiffness (Fig. 1C) . We used varying concentrations of hyaluronidase to understand the behavior of this degradation. For 100 mg/mL HA hydrogels, we observed an initial linear phase of degradation that was dependent on concentration of hyaluronidase (Fig. 3B) . This was followed by a second slow phase of degradation that was independent of hyaluronidase concentration. These data suggest that these HA hydrogels are first degraded through an enzyme mediated mechanism which break up the accessible HA chains on the surface of the hydrogels. When there is high crosslinking density, the enzyme will only degrade the exterior of the hydrogel, resulting in surface erosion. In contrast, looser hydrogel networks allow the enzyme to penetrate the interior and cause bulk degradation. This is also apparent by morphological analysis wherein lower weight percent HA hydrogels gradually lost mechanical integrity and eventually completely dissolved, while higher percent HA hydrogels became smaller over time, indicating surface degradation.
The goal of this study was to design and fabricate microstructures that can treat the progression of cardiac fibrosis post-MI to improve functional outcomes. These HA microrods act through mechanotransduction pathways to reduce fibrosis and maintain the structural integrity of the myocardium. Additionally, crosslinked HA can be compared to high molecular weight HA, which has anti-inflammatory effects that can limit pathological ECM remodeling during the initial days after an infarct [43, 49, 50] . Throughout degradation, these HA microrods are expected to release HA oligosaccharides that have been demonstrated to promote wound healing [51] . While it is difficult to investigate and tune the temporal interplay of mechanotransduction pathways and biochemical HA signaling pathways, our findings demonstrate that these two modes of action have significant implications for cardiac regeneration. By probing these individual pathways and responses, we will be able to optimize this novel microstructure-based technology to initially reduce the aberrant fibrotic response with micromechanical cues and later stimulate vascularization and other endogenous repair mechanisms for comprehensive myocardial repair.
Conclusions
Our acellular microrod approach is unique and provides biodegradable and bioactive micromechanical signals to directly limit fibrosis and favorably influence the microenvironment to attenuate myocardial wall thinning and improve LV function. These microrods were produced in a range of physiologically relevant stiffness and are able to degrade in the presence of natural enzymes. Introduction of these microrods to the injured heart provided anchors to surrounding cells during initial inflammatory processes when the ECM is being degraded. This micromechanical interaction attenuated the fibrotic phenotype and improved morphological and functional outcomes in a rat ischemiareperfusion model of MI. In the future, this innovative strategy can be co-implemented with pharmacologic and cell-based therapies to further advance our limited clinical capabilities in treating the chronic complications of MI.
Materials and methods
Synthesis of hyaluronic acid methacrylate
Hyaluronic acid methacrylate was synthesized based on a method published by Bencherif et al. [27] . Briefly, sodium hyaluronate (100 kDa) was dissolved in a solution of 1:1 deionized water:dimethylformamide at 3.75 mg/mL. A 100-fold molar excess of glycidyl methacrylate and 35-fold molar excess of triethylamine was then added. The reaction was allowed to proceed for 24 h at room temperature and away from light. Hyaluronic acid and hyaluronic acid methacrylate were recovered by precipitation in an excess of isopropanol. The precipitate was then pelleted by centrifugation at 700 Â g for 5 min and dissolved in 50 mL of water.
The resulting solution was dialyzed against water for 48 h with three changes and lyophilized for 3 days at À40 C and 65 mtorr to yield a dry powder. Degree of methacrylation was determined by 1 H NMR in D 2 O using a Bruker Avance III HD 400 NMR.
Microrod fabrication
Hyaluronic acid methacrylate was dissolved in DI water containing 0.5% w/v of 2-hydroxy-4 0 -(2-hydroxyethoxy)-2-methylpropiophenone. Once fully dissolved, the solution was centrifuged at max speed for 5 min to remove impurities. A 15 mm thick layer of this solution was deposited onto a piranha cleaned silicon wafer and exposed through a photomask to a 365 nm UV light source using a Karl Suss Mask Aligner to crosslink the hyaluronic acid methacrylate in rod shapes (15 mm Â 100 mm). The microrods were then gently scraped off the surface of the wafer using a cell scraper and collected into water, where uncrosslinked regions of hyaluronic acid methacrylate would fully dissolve. The microrods were passed through a 150 mm mesh filter to remove large particles and washed thoroughly by centrifugation. The microrods were sterilized with 70% ethanol and resuspended in saline or cell culture medium prior to use. Microrods were imaged using differential interference contrast (DIC). To visualize 3D geometry, HA microrods were labeled with 4'-(aminomethyl)fluorescein (Thermofisher, Waltham, MA) through EDC/NHS coupling and imaged using confocal microscopy.
Characterization of hyaluronic acid methacrylate stiffness
Crosslinked hyaluronic acid methacrylate hydrogels were fabricated in a range of concentrations. The stiffness of these hydrogels was determined by atomic force microscopy using a MFP3D-BIO inverted optical AFM (Asylum Research) mounted on a Nikon TE2000-U inverted fluorescent microscope. For these measurements, a gold deposited silicon nitride cantilever (k ¼ 0.09 N/ m) with a pyramidal tip was used. Ten measurements were made for each hydrogel at 3 different locations. The average of these 30 measurements was used for each replicate. Cantilevers were calibrated using a thermal oscillation method prior to each session.
Degradation of crosslinked hyaluronic acid methacrylate
Crosslinked hyaluronic acid methacrylate hydrogels were degraded at 37 C in 100 U/mL or 10 U/mL hyaluronidase. A phosphate buffered saline condition was used as a control to evaluate hydrolysis mediated degradation. The supernatant for each hydrogel was collected and replaced with fresh buffer solution every 48 h. For each time point, the amount of uronic acid was measured using a carbazole-based reaction [28] . Briefly, 200 ml of 24 mM sodium tetraborate decahydrate dissolved in concentrated sulfuric acid was added to 50 ml of each sample and heated to 100 C for 10 min. 50 ml of 0.125% carbazole in absolute ethanol was then added to each sample and heated to 100 C for 15 min. 200 ml of each solution was analyzed in a plate reader at 530 nm. Standard solutions of known concentrations of 100 kDa HA were used as a standard. Following the last time point, all remaining hydrogels were placed in concentrated sulfuric acid and assayed to determine the total amount of HA remaining.
For HA microrods, degradation was conducted by incubating the microrods in 100 U/mL, 10 U/mL and 0 U/mL hyaluronidase at 37 C. The microrods were pelleted by centrifugation at maximum speed for 5 min. The supernatant was collected and replaced with fresh buffer solution. Uronic acid was quantified as described above.
Cell culture and qPCR
NIH-3T3 mouse fibroblasts (ATCC, Manassas, Virginia) were cultured in the complete medium consisting of Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum and 1% penicillin/ streptomycin. Cells were harvested and cultured with HA microrods (100 mg/mL) at a high ratio (1:5) or a low ratio (1:20) of microrods to cells. Cell proliferation was assessed at 24, 48 and 72 h after initial seeding using a CyQUANT assay. Experiments were done in triplicate. Genetic material was harvested and purified using the RNeasy Miniprep kit. RNA was converted into cDNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). A Viia7 qPCR machine (Life Technologies, Carlsbad, CA) was used to measure relative expression levels of gene targets as compared to a housekeeping gene. Expression levels of all genes were evaluated using SYBR Green Mastermix (Life Technologies, Grand Island, NY) and custom-made DNA primers (Integrated DNA Technologies, Coralville, IA) in triplicate for three biological replicates (See Supplementary Table 1 ).
Neonatal rat ventricular myocyte (NRVM) and fibroblast (NRVF) culture
Primary heart cultures were obtained from neonatal rats according to Institutional and National Institutes of Health guidelines. Hearts were removed from 1-to 2-day-old Sprague-Dawley rats and cells isolated using collagenase type II (Worthington Biochemical, Lakewood, NJ), per previously established protocol [52] . Fibroblasts, which had been separated from myocytes during isolation, were cultured an additional 2 days before detaching cells with trypsin and seeding in new dishes for experiments.
Kymograph analysis of cardiomyocyte contractility
Neonatal ventricular cardiomyocytes were plated on fibronectin-coated dishes (10 mg/mL) or fibronectin-coated dishes with HA previously deposited (10,000 HA microrods/dish). A subset of dishes were chronically exposed to hyaluronic acid (0.042 mg) starting on the plating day. On the second day of incubation, kymographs derived from line scans with DIC illumination were used to derive cardiomyocyte contractile properties as described previously [29] . For HA microrods, line scans were developed on myocytes with close proximity to the HA microrods.
Infarct model and microrod injections
The animal protocol for induction of MI was approved by the Committee for Animal Research of the University of California San Francisco and was performed in accordance with the recommendations of the American Association for Accreditation of Laboratory Animal Care. The ischemia-reperfusion model used in this study has been extensively tested in our lab. All injections were performed successfully and there were no complications resulting from surgery or injection in any animal. Protocols were approved by the IACUC of UCSF.
To produce the MI model, female Sprague-Dawley rats (180e220 g) underwent occlusion of the left anterior descending coronary artery for 30 min followed by reperfusion while under general anesthesia achieved by inhalation of 2% L/min isoflurane [53] . The chest was then closed and the animal was allowed to recover. The rats were randomized two days after MI to salineinjected, HA solution-injected, or microrod-injected treatment groups, and were given one intramuscular injection into the heart wall under blinded conditions via ultrasound guided transthoracic injection using a 29-gauge syringe [53] . Each injection consisted of 50 mL of sterile 0.9% sodium chloride solution (n ¼ 7), HA dissolved in sodium chloride solution at 4.2 mg/mL (n ¼ 9), or 50,000 microrods in sodium chloride solution (n ¼ 7). Preliminary studies showed that 75 mg/mL HA microrods outperformed the 100 mg/mL microrods. 75 mg/mL HA microrods were used for all microrods injections presented in this study. Each injection was delivered to the center of the infarct region as visualized by hyperechoic signal on ultrasound. Successful injection was confirmed by a slight local increase in ultrasound signal in the vicinity of the syringe, as well as a brief thickening of the LV wall.
Echocardiography
Transthoracic echocardiography was performed with a 15-MHz linear array transducer system (Sequoia c256, Acuson, Erlangen, Germany) on all animals under 2% L/min isoflurane. Echocardiography was done prior to injection on day two post-MI and six weeks post-injection using standard methods that have been performed reproducibly in our lab [24, 53] . To determine left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) and ejection fraction (EF) at 48 h and six weeks, the ventricular shadow was outlined in both systole and diastole and the single plane area length algorithmic method was applied. Twodimensional images were obtained in both parasternal long-and short-axis views at the papillary muscle level. Stroke volume (SV) was calculated by SV ¼ LVEDV-LVESV, while change in EF was calculated by DEF ¼ EF 6 weeks -EF 2 days . Transverse images were obtained at three levels: basal (at the tip of the mitral valve leaflets), middle (at the papillary muscle level), and apical (distal to papillary muscle but before the cap of the cavity). All image analyses were performed in a blinded fashion. In cases where the ventricular shadow was not clearly identifiable in the 48 h or six week image, the heart in question was excluded from echocardiographic analyses. Cases where ejection fraction was above 50% at 48 h were excluded because they indicated an insufficient infarct model.
Histology
Sacrifice was performed after six weeks by maintaining the animal at 5% L/min isoflurane for 5 min, followed by bilateral thoracotomy and injection of potassium chloride into the right atrium to arrest the heart in diastole. The heart was then extracted and frozen in OCT (Sakura Finetech USA, Inc., Torrance, CA) on 2-methylbutane (Sigma Aldrich, St. Louis, MO) on dry ice and sectioned for histology and image analysis. Tissue blocks were cryosectioned at a thickness of 10 mm starting at the apex of the left ventricle and collecting 10 serial sections every 350 mm until 100 sections were collected. Sections were stained with H&E stains, Masson's trichrome stain and Picrosirius red stains using standard protocols. For immunofluorescent stains, tissue sections were air dried and blocked with 10% serum, followed by incubation with primary and secondary antibodies using standard protocols. In brief, samples were incubated overnight with primary antibodies at 4 C in a solution of 0.1% Triton X-100, 0.05% Tween-20, 10% goat serum and 1% BSA in PBS (anti-vimentin, anti-CD68, anti-paxillin; Abcam, Cambridge, United Kingdom). After rinsing, secondary antibody was added for 45 min at room temperature. DAPI and AlexaFluor 546 phalloidin were added as a counterstain (Thermofisher, Waltham, MA).
Image analysis
A Zeiss LSM 710 confocal microscope at UIC was used for fluorescence imaging of myocyte and fibroblast interactions with HA microrods in vitro. Single-plane and Z-stack images were obtained using a 63Â Zeiss objective. Primary antibodies for paxillin [ab32084] and CD44 [ab157107] (Abcam, Cambridge, MA) were used at 1:250 and 1:1000 dilutions, respectively, incubated overnight, then counterstained with secondary antibody (A21207, Thermofisher, Waltham, MA), rhodamine phalloidin (R415, Thermofisher, Waltham, MA), and DAPI (H-1200, Vector Laboratories, Burlingame, CA).
Visualization of fibronectin bound to microrods was conducted by incubating HA microrods for 2 h at 37 C in 10 mg/mL of fibronectin in PBS, or in PBS alone as a control. Fibronectin was eliminated by three cycles of centrifugation and resuspension in PBS.
Microrods were incubated with a fibronectin antibody (ab26245, Abcam, Cambridge, MA) at a 1:1000 dilution for 1 h at 37 C before centrifugation and resuspension in PBS three times; then, microrods were incubated with fluorescently-labeled secondary antibody (A21202, Thermofisher, Waltham, MA) at a 1:400 dilution for 1 h at room temperature before imaging in a fluorescence microscope. For whole heart histology, images were taken using a Nikon 6D optical microscope (NIKON Instruments, Inc., Melville, NY) with 4e20Â magnification (H&E, Masson's trichrome, Picrosirius red) and a Nikon spinning disc confocal microscope. All quantifications were performed using Nikon Elements. For wall thickness analysis, the minimum length across the infarct area was measured for each tissue section. The absolute minimum length across all available sections in a given heart sample was selected as the minimum wall thickness.
For collagen analysis, five sections of each heart were selected from throughout the coronal plane of the infarct zone and stained with Picrosirius red to assess the distribution and density of collagen in the injured hearts. These sections were imaged under brightfield as well as under polarized light to visualize the collagen fibers. Infarct area was quantified and normalized to total area of the left ventricular free wall.
Statistical analysis
All values for continuous variables are listed as the mean ± one standard deviation, unless otherwise indicated. In vitro and in vivo analysis was performed using a one-way analysis of variance (ANOVA), followed by multiple comparison by Holm-Sidak correction to identify differences between groups.
